Menactra

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MalariaPlasmodium Falciparum MalariaDiphtheria

479 competitors in Malaria

#DrugCompanyPhaseTrials

1

Menactra

GSK

Approved

12

Biltricide

Bayer

Preclinical

13

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

16

IV LBH589

Novartis

Preclinical

17

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

18

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

19

RTS,S/AS01E

GSK

Preclinical

410

Piperaquine

UUniversity of Oxford

Preclinical

3Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity4 trials

Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors

Unknown status·—·Phase 4·NCT04224311·102 enrolled

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

Completed·GSK·Phase 2·NCT00454909·873 enrolled

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Completed·GSK·Phase 2·NCT01165242·1,013 enrolled

Show 1 more trial

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age

Completed·SSerum Institute of India Pvt. Ltd.·Phase 2/3·NCT04358731·1,640 enrolled

Vaccine3 trials

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Completed·SSerum Institute of India Pvt. Ltd.·Phase 2·NCT03295318·375 enrolled

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

Completed·PPATH·Phase 1·NCT02810340·60 enrolled

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Completed·SSerum Institute of India Pvt. Ltd.·Phase 3·NCT03964012·1,800 enrolled

Plasmodium Falciparum2 trials

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03917654·1,301 enrolled

Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02942277·301 enrolled

Malaria1 trial

Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01867463·230 enrolled

Plasmodium falciparum malaria1 trial

Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02334462·538 enrolled

2 more indications

Single Dose1 trial

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Completed·Sanofi··NCT00862277·763 enrolled

Diphtheria1 trial

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Completed·GSK·Phase 4·NCT00282295·1,344 enrolled

Details

Drug Info

Related News